HMG-box transcription factor 1 (HBP1) had been described as a negative regulator of the Wnt/β-catenin signaling in many cancers, including breast cancer (33), osteosarcoma (34), glioma (35), and colorectal carcinoma (36). Here, HBP1 is linked to central nervous system cancer.